CD99
单克隆抗体
尤因肉瘤
肉瘤
癌症研究
阿霉素
抗原
细胞凋亡
医学
骨髓
抗体
化疗
化学
免疫学
免疫组织化学
病理
内科学
生物化学
波形蛋白
作者
Katia Scotlandi,Stefania Perdichizzi,Ghislaine Bernard,Giordano Nicoletti,Patrizia Nanni,Pier‐Luigi Lollini,Antonio Curti,Maria Cristina Manara,Stefania Benini,Alain Bernard,Piero Picci
标识
DOI:10.1016/j.ejca.2005.09.015
摘要
CD99 is a 32kDa surface glycoprotein that is involved in the migration of leukocytes, cell-cell adhesion and apoptosis of T cells and Ewing's sarcoma (ES) cells, two cell types with a high level of CD99 expression. Engagement of the molecule induces a rapid death signal that appears to be related to the level of expression of this antigen. The rapid apoptosis induced by agonistic anti-CD99 monoclonal antibodies is of clinical interest in ES, a tumour for which no new drugs have been described as clearly effective in the last 10 years. In this study, we show that an anti-CD99 monoclonal antibody can be used to advantage in association with doxorubicin. Striking effectiveness was observed against local tumours and metastases. No remarkably toxic effects of anti-CD99 monoclonal antibody were found in bone marrow against blood precursors. These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES.
科研通智能强力驱动
Strongly Powered by AbleSci AI